Molecular glues act as "molecular adhesives”, facilitating or stabilizing interactions between proteins that might not otherwise bind strongly or at all. Molecular glues show great potential for treating diseases such as cancer and infectious, inflammatory, and neurodegenerative diseases.
A key application of molecular glues is in targeted protein degradation, where they facilitate the proximity of a target protein to an E3 ubiquitin ligase, resulting in the protein's degradation. New modalities, such as molecular glues, require robust screening strategies to identify and develop the most promising candidates efficiently.
This expert-led presentation will introduce WuXi Biology’s end-to-end molecular glue discovery platform. Using advanced screening technologies, assays, and cutting-edge animal models, our platform allows for extensive in vitro and in vivo characterization of these unique molecules. This webinar offers an in-depth perspective on strategies crucial for accelerating research focused on the development of molecular glue-based therapeutics.
Key Learning Objectives:
- Explore how molecular glues drive targeted protein degradation and why effective screening is key to discovering viable candidates;
- Learn advanced screening and assay technologies tailored for identifying and characterizing molecular glue candidates;
- Get a front-row look at WuXi Biology’s end-to-end discovery platform, from screening to in vivo validation.
Who Should Attend:
- Researchers working on molecular glue drug discovery
- Researchers interested in strategies and approaches for lead optimization of molecular glues
- Research teams focused on bifunctional molecules and new modalities for “undruggable” targets